Novartis Quarterly Profit Drops Less Than Analysts Expected

Novartis Quarterly Profit Drops Less Than Analysts Expected


Novartis AG posted a smaller decline in second-quarter profit than analysts had projected amid early signs of a revival at its Alcon eye-care division and as new medicines helped offset the eroding sales of its biggest drug. Alcon's revenue in 2017 will likely grow by a low "single-digit" percent, the Basel, Switzerland-based company said in a statement on Tuesday.



from Biotech News